BSE Live
Apr 13, 16:01Prev. Close
56.06
Open Price
54.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of OXYGENTA PHARMACEUTICAL (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | |
| Diluted EPS (Rs.) | -2.69 | -1.04 | -8.15 | -0.48 | 2.87 | |
| Cash EPS (Rs.) | -2.40 | -0.24 | -6.70 | 0.69 | 4.04 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | -6.77 | -6.01 | -32.53 | -24.38 | -37.27 | |
| Book Value [InclRevalReserve]/Share (Rs.) | -6.77 | -6.01 | -32.53 | -24.38 | -37.27 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 29.55 | 11.84 | 21.82 | 42.62 | 51.00 | |
| PBDIT/Share (Rs.) | -2.35 | -2.88 | -5.00 | 1.04 | 3.86 | |
| PBIT/Share (Rs.) | -2.57 | -3.68 | -6.44 | -0.08 | 2.68 | |
| PBT/Share (Rs.) | -3.12 | -4.14 | -8.01 | -0.34 | 3.08 | |
| Net Profit/Share (Rs.) | -2.62 | -1.04 | -8.15 | -0.43 | 2.87 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -7.94 | -24.35 | -22.90 | 2.44 | 7.56 | |
| PBIT Margin (%) | -8.69 | -31.06 | -29.53 | -0.18 | 5.26 | |
| PBT Margin (%) | -10.57 | -34.99 | -36.70 | -0.80 | 6.04 | |
| Net Profit Margin (%) | -8.85 | -8.77 | -37.34 | -1.00 | 5.63 | |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | 0.00 | -7.70 | |
| Return on Capital Employed (%) | 391.43 | -41.74 | -37.43 | -0.47 | 16.72 | |
| Return on Assets (%) | -11.60 | -5.50 | -21.32 | -1.95 | 8.65 | |
| Total Debt/Equity (X) | -2.49 | -2.84 | -1.47 | -1.51 | -1.26 | |
| Asset Turnover Ratio (%) | 1.49 | 0.68 | 0.73 | 1.86 | 153.63 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.36 | 0.72 | 0.84 | 1.19 | 0.91 | |
| Quick Ratio (X) | 0.12 | 0.31 | 0.45 | 0.28 | 0.22 | |
| Inventory Turnover Ratio (X) | 6.39 | 2.76 | 2.96 | 4.40 | 4.29 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 356.35 | 154.20 | 119.86 | 86.13 | 54.89 | |
| EV/Net Operating Revenue (X) | 3.26 | 3.89 | 3.87 | 1.42 | 1.06 | |
| EV/EBITDA (X) | -41.03 | -15.97 | -16.88 | 58.17 | 13.95 | |
| MarketCap/Net Operating Revenue (X) | 2.69 | 2.45 | 1.68 | 0.56 | 0.14 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | -11.76 | -4.82 | -1.13 | -0.99 | -0.20 | |
| Price/Net Operating Revenue | 2.69 | 2.45 | 1.68 | 0.56 | 0.14 | |
| Earnings Yield | -0.03 | -0.04 | -0.22 | -0.02 | 0.39 |
09.02.2026
OXYGENTA PHARMA Standalone December 2025 Net Sales at Rs 33.93 crore, up 2.18% Y-o-Y
12.11.2025
OXYGENTA PHARMA Standalone September 2025 Net Sales at Rs 14.30 crore, up 2.12% Y-o-Y
11.06.2025
OXYGENTA PHARMA Standalone March 2025 Net Sales at Rs 49.47 crore, up 368.77% Y-o-Y
25.11.2024
OXYGENTA PHARMA Standalone September 2024 Net Sales at Rs 14.01 crore, up 7.11% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth